Neurogene
NGNE
85 hedge funds and large institutions have $193M invested in Neurogene in 2025 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 29 increasing their positions, 24 reducing their positions, and 17 closing their positions.
33.54% more ownership
Funds ownership: 76.7% → 110.24% (+34%)
21% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 24
3% less funds holding
Funds holding: 88 → 85 (-3)
18% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 17
48% less capital invested
Capital invested by funds: $368M → $193M (-$175M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
59% less call options, than puts
Call options by funds: $1.19M | Put options by funds: $2.93M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$14.1M |
| 2 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
+$4.16M |
| 3 |
Millennium Management
New York
|
+$2.74M |
| 4 |
CC
Commodore Capital
New York
|
+$2.17M |
| 5 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$2.03M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.9M |
| 2 |
JP Morgan Chase
New York
|
-$6.84M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$2.82M |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$2.41M |
| 5 |
BlackRock
New York
|
-$2.03M |
NGNE Hedge Fund Activity: Q1 2025 in Review
85 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Neurogene (NGNE) for Q1 2025, worth a combined $193M — down 48% from $368M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of NGNE and 14 opened new positions — a net loss of 3 holders — while 24 trimmed existing stakes and 29 added.
The largest buyer was Baker Bros. Advisors, adding an estimated $14.1M. The largest seller was Fidelity Investments, cutting an estimated $6.9M.
- 85 institutional investors held Neurogene (NGNE) as of Q1 2025, down from 88 in Q4 2024.
- Funds reported $193M of Neurogene stock for Q1 2025, down 48% quarter-over-quarter.
- 14 funds opened new Neurogene positions in Q1 2025 and 17 closed out, a net change of -3 holders.
- The largest Neurogene buyer in Q1 2025 was Baker Bros. Advisors, an estimated $14.1M added.
- The largest Neurogene seller in Q1 2025 was Fidelity Investments, an estimated $6.9M sold.
Based on aggregated 13F filings for Q1 2025.